#GLP-1 #HSA More articles by Matt Clarkin CHSA, FCS In Today's HSA Q&A, we answer whether someone still make the maximum HSA contribution for 2025, if they weren't HSA-eligible for the full year
A key trial found that 600mg per day provided the best balance of effectiveness and tolerability, reducing instances of nausea, dizziness, and GI discomfort.4 A separate review of multiple studies supports this, concluding that 600mg daily is effective and well-tolerated for conditions like diabetic neuropathy, insulin resistance, and oxidative stress.5 That body of research has established 600mg of racemic ALA as a standard dose in clinical studies, thanks to its consistent balance of efficacy and tolerability
Choosing the right protein sources while managing a suppressed appetite requires strategic planning but pays enormous dividends in results
Challenges and future directions Currently, GLP-1RAs have shown potential for mitigating neurodegeneration